Volume 19, Number 8—August 2013
CME ACTIVITY - Research
Extended-Spectrum β-Lactamase–producing Enterobacteriaceae among Travelers from the Netherlands
Table 1
Destination | No. travelers | No. (%) travelers with ESBL-E after return | Incidence proportion, % (SE) | Person-days, all travelers | Mean duration of travel, all travelers, d | ESBL incidence rate/100 pdt (SE) |
---|---|---|---|---|---|---|
Southeast Asia | 110 | 37 (34) | 34 (4.5) | 2,980 | 27 | 1.24 (0.20) |
East Asia | 33 | 22 (67) | 67 (8.3) | 776 | 24 | 2.83 (0.60) |
South Asia | 25 | 18 (72) | 72 (9.2) | 599 | 24 | 3.01 (0.70) |
Central Asia | 3 | 1 (30) | 33 (33.3) | 94 | 31 | 1.06 (1.06) |
North Africa | 10 | 4 (40) | 40 (16.3) | 112 | 11.2 | 3.57 (1.76)† |
Central Africa | 56 | 17 (30) | 30 (6.2) | 1,637 | 29 | 1.04 (0.25) |
Southern Africa | 26 | 3 (12) | 12 (6.6) | 631 | 25 | 0.48 (0.27) |
Middle East | 15 | 2 (13) | 13 (9.1) | 222 | 14.8 | 0.90 (0.64) |
Central America and the Caribbean | 28 | 7 (25) | 25 (8.3) | 544 | 19 | 1.29 (0.48) |
South America |
32 |
2 (6) |
6 (4.4) |
922 |
29 |
0.22 (0.15) |
Total | 338 | 113 (33) | 33 (2.6) | 8,536 | 25 | 1.32 (0.12) |
*ESBL-E, extended-spectrum β-lactamase–producing Enterobacteriaceae; SE, standard error; pdt, person-days of travel.
†The ESBL incidence rate/100 pdt is represented by 4 travelers returning from North Africa who carried ESBL-E: 3 of them had traveled for 7 days and 1 had a 25-day stay abroad, which accounts for the high SE.
1These authors contributed equally to this article.
Page created: July 26, 2013
Page updated: July 26, 2013
Page reviewed: July 26, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.